Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Claritev CorporationNYSE: CTEV
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $98.93M rose 35.2% year over year, ahead of the -56.0% change in trailing-twelve-month financing cash flow.
Context
- Financing cash flow amounted to 0.2% of revenue in FY2025, down 4.2 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +35.2% holds above the trailing-twelve-month pace of -56.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 2.36M USD
- Year-over-year change
- +105.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.36M | +105.7% |
| FY2024 | 2024-12-31 | (41.32M) | +77.2% |
| FY2023 | 2023-12-31 | (180.99M) | -56.4% |
| FY2022 | 2022-12-31 | (115.74M) | -0.9% |
| FY2021 | 2021-12-31 | (114.68M) | — |
Financing Cash Flow vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 financing cash flow of $28.15M is the 8th largest of the 11 companies compared; the peer median is $15.61M.
- Its year-over-year change of -56.0% is the 8th highest of 11, against a peer median of +105.3%.
- Financing cash flow amounts to 2.9% of revenue for CTEV, versus a peer median of 18.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B | +2428.7% | +42.6% | 54053.9% | |
| LTM Sep 2026 | $293.55M | +4152.5% | +80.2% | 110.0% | |
| LTM Mar 2026 | $147.75M | -259.9% | — | 7.8% | |
| LTM Mar 2026 | $145.87M | -48.2% | +24.9% | 18.5% | |
| LTM Mar 2026 | $127.62M | +790.4% | +197.0% | — | |
| LTM Mar 2026 | $119.19M | -174.7% | — | 20.5% | |
| LTM Mar 2026 | $66.66M | -82.6% | +45.3% | 17.8% | |
CTEVClaritev Corporation | LTM Mar 2026 | $28.15M | -56.0% | — | 2.9% |
| LTM Mar 2026 | $17.93M | +109.1% | +11.5% | 20.8% | |
| LTM Mar 2026 | $13.29M | +242.2% | +193.9% | 6.1% | |
| LTM Mar 2026 | $1.26M | +101.5% | — | 0.1% | |
| Peer median (excluding CTEV) | $15.61M | +105.3% | +45.3% | 18.5% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Depreciation & Amortization | 424.32M | 415.66M | 425.79M | 436.44M | 445.43M |
| Deferred Income Tax | (81.93M) | (114.38M) | (114.06M) | (198.01M) | (128.51M) |
| Stock-Based Compensation | 18.01M | 16.74M | 18.02M | 26.65M | 27.82M |
| Change in Working Capital | (46.68M) | 55.34M | (21.91M) | (13.67M) | (28.87M) |
| Accounts Receivables | (33.83M) | 21M | 4.4M | (13.2M) | (26.57M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.71M | 34.35M | 5.58M | 42.22M | (25.86M) |
| Other Working Capital | (12.85M) | 34.34M | (26.31M) | (42.69M) | 23.57M |
| Other Non-Cash Items | (93.04M) | 571.92M | (44.42M) | 1.5B | 85.73M |
| Operating Cash Flow | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Capital Expenditures | (84.59M) | (89.74M) | (108.85M) | (118.12M) | (129.6M) |
| Acquisitions (Net) | (149.43M) | 0 | (140.94M) | 0 | 0 |
| Purchases of Investments | 0 | (15M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 289K | 0 | 0 | 16M |
| Other Investing Activities | 5.64M | 0 | 0 | 0 | (7.42M) |
| Investing Cash Flow | (228.38M) | (104.45M) | (249.79M) | (118.12M) | (121.02M) |
| Debt Repayment | (10.9M) | (13.28M) | (165.82M) | (28.07M) | 4.72M |
| Common Stock Issued | 0 | 0 | 508K | 0 | 1.74M |
| Common Stock Repurchased | (103.79M) | (100M) | (15.22M) | (10.37M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.79M) | (2.46M) | (465K) | (2.88M) | (4.1M) |
| Financing Cash Flow | (114.68M) | (115.74M) | (180.99M) | (41.32M) | 2.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 61.62M | 152.18M | (259.07M) | (51.82M) | (1.33M) |
| Free Cash Flow | 320.1M | 282.63M | 62.87M | (10.51M) | (12.28M) |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.